KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioMarket CapitalizationNet MarginOperating MarginReturn on SalesTimes Interest Earned

Palvella Therapeutics (PVLA) EBITDA Margin: 2014-2024

Historic EBITDA Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to 1,859.67%.

  • Palvella Therapeutics' EBITDA Margin fell 106250.00% to 1,859.67% in Q4 2024 from the same period last year, while for Dec 2024 it was -1,832.91%, marking a year-over-year decrease of 187466.00%. This contributed to the annual value of 4,053.72% for FY2024, which is 401187.00% up from last year.
  • According to the latest figures from Q4 2024, Palvella Therapeutics' EBITDA Margin is 1,859.67%, which was down 41.29% from 3,167.73% recorded in Q3 2024.
  • Over the past 5 years, Palvella Therapeutics' EBITDA Margin peaked at 3,167.73% during Q3 2024, and registered a low of -5,150.94% during Q1 2024.
  • For the 3-year period, Palvella Therapeutics' EBITDA Margin averaged around 130.12%, with its median value being -56.12% (2023).
  • Over the last 5 years, Palvella Therapeutics' EBITDA Margin had its largest YoY gain of 322,384bps in 2024, and its largest YoY loss of 448,652bps in 2024.
  • Palvella Therapeutics' EBITDA Margin (Quarterly) stood at -741.24% in 2020, then skyrocketed by 63,086bps to -110.38% in 2021, then slumped by 4,152bps to -151.90% in 2022, then skyrocketed by 307,407bps to 2,922.17% in 2023, then crashed by 106,250bps to 1,859.67% in 2024.
  • Its last three reported values are 1,859.67% in Q4 2024, 3,167.73% for Q3 2024, and -5,150.94% during Q1 2024.